SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- As the global leader in advanced MRI post-processing solutions, Cortechs.ai is proud to highlight the unmatched capabilities of NeuroQuant® ARIA, the first FDA-cleared tool to offer processing for both Gradient-Recalled Echo (GRE) and Susceptibility-Weighted Imaging (SWI) sequences.
With over 60 days since the 510(k) clearance, NeuroQuant ARIA has already been adopted by major institutions, further solidifying its position as the go-to technology for identifying and quantifying cerebral microhemorrhages and superficial siderosis. "With an estimated 1.5 million US patients with early Alzheimer's disease now candidates for disease modifying therapy, the need for accurate and efficient ARIA surveillance MRI interpretation becomes paramount.
I am excited about how NeuroQuant® ARIA raises the bar in patient care through its enhanced deep learning based technology which allows precise automated detection, segmentation, radiographic grading, and longitudinal follow-up of blood products and edema on MRI. This extremely valuable tool enhances ARIA surveillance accuracy and efficiency while reducing reader subjectivity," says Suzie Bash , MD. Cortechs.
ai is the only organization capable of processing both GRE and SWI sequences—setting a new standard for comprehensive and reliable imaging solutions. This capability is essential in today's diagnostic landscape, where radiologists demand faster, more precise imaging tools to ensure accurate as.